Bioxcel therapeutics announces plan for evaluating bxcl501 in the at-home setting to expand its market potential

Company plans to initiate serenity at-home pivotal phase 3 safety trial with 120 mcg dose following recent meeting with fda
BTAI Ratings Summary
BTAI Quant Ranking